Drug Trial Radar · NCT04315298
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Last checked: Nov 20, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,912
Actual
Start
Mar 18, 2020
Primary completion
Jul 24, 2020
Study completion Sep 2, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Mar 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata. Phase 3 Cohort 1: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline. Phase 3 Cohort 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.
Conditions
- COVID-19
Interventions
SarilumabDrug
Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
PlaceboDrug
Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)Time frame: Baseline and Day 4
- Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)Time frame: Day 22
- Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)Time frame: Day 22
Locations
62 sites in 1 country. Site status is shown where the registry gives one.
Regeneron Study Site
Los Angeles, California
Regeneron Study Site
Sacramento, California
Regeneron Study Site
Santa Monica, California
Regeneron Study Site
Aurora, Colorado
Regeneron Study Site
Denver, Colorado
Regeneron Study Site
New Haven, Connecticut
Regeneron Study Site
Washington D.C., District of Columbia
Regeneron Study Site
Gainesville, Florida
Regeneron Study Site
Orlando, Florida
Regeneron Study Site
Tampa, Florida
Regeneron Study Site
Atlanta, Georgia
Regeneron Study Site
Decatur, Georgia
Regeneron Study Site
Marietta, Georgia
Regeneron Study Site
Chicago, Illinois
Regeneron Study Site
Chicago, Illinois
Regeneron Study Site
New Orleans, Louisiana
Regeneron Study Site
Boston, Massachusetts
Regeneron Study Site
Boston, Massachusetts
Regeneron Study Site
Boston, Massachusetts
Regeneron Study Site
Ann Arbor, Michigan
Regeneron Study Site
Rochester, Minnesota
Regeneron Study Site
Edison, New Jersey
Regeneron Study Site
Hackensack, New Jersey
Regeneron Study Site
Livingston, New Jersey
Regeneron Study Site
Morristown, New Jersey
Regeneron Study Site
Neptune City, New Jersey
Regeneron Study Site
Newark, New Jersey
Regeneron Study Site
Teaneck, New Jersey
Regeneron Study Site
Brooklyn, New York
Regeneron Study Site
Buffalo, New York
Regeneron Study Site
Elmhurst, New York
Regeneron Study Site 1
Manhasset, New York
Regeneron Study Site 2
Manhasset, New York
Regeneron Study Site
New York, New York
Regeneron Study Site
New York, New York
Regeneron Study Site 1
New York, New York
Regeneron Study Site 2
New York, New York
Regeneron Study Site
New York, New York
Regeneron Study Site
New York, New York
Regeneron Study Site
New York, New York
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.